Global EYLEA Drug Market Analysis

Global EYLEA drug market size is expected to reach US$ 14.30 Bn by 2030, from US$ 8.79 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period. EYLEA (aflibercept) is an anti-vascular endothelial growth factor (Anti-VEGF) medication used to treat several eye disorders including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). It works by inhibiting the abnormal growth of blood vessels in the eye, thereby preventing leakage and swelling that can cause vision loss. EYLEA helps improve vision and reduce the risk of blindness in patients suffering from these retinal diseases.

Rising prevalence of diabetes and age-related eye diseases is a major factor driving the EYLEA drug market growth. Growing geriatric population which is more susceptible to eye disorders is also fueling the demand for EYLEA. Moreover, the rising awareness about retinal diseases and the availability of favorable reimbursement for EYLEA injections are other factors propelling the market growth.

Global Eylea Drug Market Drivers

• Increasing geriatric population: Increasing geriatric population globally will aid in the market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) in October 1, 2022, the number of people aged 60 years and older outnumbered children younger than 5 years, in 2020,
• Strong Clinical Efficacy Profile of EYLEA: EYLEA has demonstrated strong efficacy in treating wet AMD and other retinal diseases in multiple large clinical trials, thereby leading to its approval for these indications. In the VIEW 1 and VIEW 2 trials, EYLEA showed non-inferiority and comparable efficacy to ranibizumab in improving vision in wet AMD patients. The VIVID and VISTA trials established EYLEA’s efficacy in significantly improving vision and reducing central retinal thickness in DME patients. Such positive clinical data has augmented trust in the performance of EYLEA, thereby encouraging its adoption.

Global Eylea Drug Market Opportunities

• High growth potential in emerging countries: Emerging markets such as Asia Pacific and Latin America present significant growth opportunities for EYLEA, due to the high patient pool, growing healthcare expenditure, and expanding access to eye care in these regions. For instance, according to the data published by the World Bank, in April 2023, India’s health expenditure was 2.96% of gross domestic product in 2020.

Global Eylea Drug Market Restraints

• Side Effects: Side effects of eylea are expected to hinder the market growth over the forecast period. There few side effects of eylea which includes increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.

Counterbalance: The key market players need to focus on reducing the side effects of the EYLEA drug at the time of its manufacturing processes, so that it gets accepted by the population and help in driving the market growth of the EYLEA drug.

Analyst’s View on Global Eylea drug market:

Global eylea drug market is expected to witness high growth over the forecast period due to increasing prevalence of eye diseases, as well as increasing geriatric population globally which is expected to drive the global EYLEA drug market growth. Moreover, the patent of the brand is expected to expire after in 2025, which is expected to generate high revenues.